Abstract : The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common adverse events of PFD are skin manifestations (25%), described as photosensitivity or rash, but they are not well characterized. The objective of the present real-life study was to address the question of skin manifestations in patients treated with PFD for IPF.
C Droitcourt, Henri Adamski, A Polat, E Polard, M Kerjouan, et al.. Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series. British Journal of Dermatology, Wiley, 2018, 178 (3), pp.e222-e223. ⟨10.1111/bjd.16016⟩. ⟨hal-01771415⟩
